SMS Pharmaceuticals Share Price Jumps 6% After Clean USFDA Inspection

Market Performance

The share price of SMS Pharmaceuticals soared in early trade on June 26, 2025, following positive regulatory news from the United States Food and Drug Administration (USFDA).

• Current Share Price: ₹254.65
• Gain: ₹15.60 or +6.53% on BSE
• 52-Week High: ₹398.00 (September 23, 2024)
• 52-Week Low: ₹175.00 (April 7, 2025)
• Distance from High: 36.02% below
• Distance from Low: 45.51% above
• Market Capitalisation: ₹2,257.52 Crore

The recent jump in the SMS Pharmaceuticals share price reflects investor confidence following a clean regulatory inspection.

Main News

On June 25, 2025, SMS Pharmaceuticals announced that the USFDA concluded an inspection at its Central Laboratory Analytical Services in Gagillapur Village, Hyderabad.

• Inspection Dates: June 23–25, 2025
• Outcome: Zero Form 483 observations
• Facility Type: Independent testing laboratory

This was the second successful USFDA inspection for the Central Laboratory facility. The company reaffirmed its dedication to maintaining top-tier quality standards, strictly adhering to CGMP and GLP regulations.

Additionally, on May 30, SMS Pharmaceuticals received an Establishment Inspection Report for its API manufacturing facility in Bachupally, Hyderabad, based on an inspection conducted in March 2025.

Company Details

SMS Pharmaceuticals is a Hyderabad-based pharmaceutical firm focused on active pharmaceutical ingredients (APIs) and analytical services. The company continues to strengthen its compliance track record with global regulators.

Recent developments have reflected positively on the company's operational capabilities and regulatory adherence, which are boosting investor sentiment and driving the share price performance of SMS Pharmaceuticals.

Financial Performance (Q4 FY25)

Revenue

• ₹248.20 Crore, up from ₹245.80 Crore (YoY)

Net Profit

• ₹20.32 Crore, a rise of 17.5% compared to ₹17.28 Crore in the same quarter last year

These numbers indicate consistent financial growth, adding another layer of strength to the company's positive outlook.

Summary

The SMS Pharmaceuticals share price rose by over 6% following a successful US FDA inspection at its Central Laboratory. With zero Form 483 observations, the inspection outcome reinforces the company's reputation for regulatory compliance. Coupled with solid financial performance in Q4 FY25, these developments have strengthened investor confidence.